Odimma Therapeutics has been awarded the European Commission’s Seal of Excellence for its ODI Platform project, recognizing the scientific quality, innovation potential and strategic relevance of the company’s personalized immunotherapy platform.
The distinction was granted under the Horizon Europe EIC Accelerator program following evaluation by an international panel of independent experts.
The ODI Platform project was recognized as a high-quality proposal in a highly competitive European evaluation process focused on breakthrough innovation and deep technology initiatives.
The project combines artificial intelligence, neoantigen prediction and synthetic DNA technologies to support the development of next-generation personalized immunotherapies designed for precision oncology applications.
The Seal of Excellence further reinforces Odimma Therapeutics’ position within Europe’s emerging oncology and biotechnology innovation ecosystem and highlights the company’s long-term vision for scalable personalized cancer treatment platforms.
